Neptune Medical Secures $97M in Funding, Launches Jupiter Endovascular Subsidiary

Neptune Medical Raises $97M:
Neptune Medical has completed a Series D financing round, securing $97 million in funding. This investment will strengthen the company's focus on gastrointestinal (GI) robotics.

Spinout of Jupiter Endovascular:
Neptune Medical has successfully spun out its subsidiary, Jupiter Endovascular, which will focus on developing novel endovascular technology platforms.

Investors and Partners:
Significant investors in the funding round include Sonder Capital and Olympus Corporation of the Americas. Other existing and new investors also participated.

Leadership and Expertise:
Dr. Fred Moll, a pioneer in surgical robotics, has been appointed as the Chairman of the Board for Neptune Medical. Carl J. St. Bernard, an industry veteran, has been appointed as the CEO of Jupiter Endovascular.

Jupiter Endovascular's Funding:
Jupiter Endovascular has received $21 million in new financing to support its upcoming pivotal trial for pulmonary embolism and to develop additional clinical applications of its Endoportal Control technology.

Technological Innovations:
Neptune Medical is expanding its focus on GI robotics, while Jupiter Endovascular aims to bring the precision and control of direct surgical access to catheter-based interventions using its Endoportal Control platform.

Strategic Moves:
The spinout of Jupiter Endovascular is a strategic move to align with Neptune Medical's long-term goals, allowing both companies to innovate within their respective specialties.